This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...
For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus ...
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...
State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements between Medicaid programs and manufacturers of gene therapies for sickle cell ...
New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However, data from ...
The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative ...
A legal technique deployed by Utah to restrict gender-affirming care for minors aims at a core component of the clinician–patient relationship: clinicians’ ability to rely on patients ...
A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation ...
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...